HC Wainwright Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $36.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target trimmed by HC Wainwright from $40.00 to $36.00 in a research report report published on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other brokerages have also weighed in on DAWN. Needham & Company LLC reissued a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, February 10th. Bank of America reduced their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $34.86.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $9.85 on Wednesday. The company has a market cap of $992.83 million, a P/E ratio of -9.56 and a beta of -1.46. Day One Biopharmaceuticals has a fifty-two week low of $9.77 and a fifty-two week high of $18.07. The stock has a 50 day simple moving average of $12.29 and a two-hundred day simple moving average of $13.44.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million. On average, research analysts predict that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total transaction of $399,300.00. Following the transaction, the insider now directly owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. This trade represents a 2.82 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Charles N. York II sold 4,370 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the sale, the chief financial officer now owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. The trade was a 1.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,064 shares of company stock valued at $651,225 over the last ninety days. 8.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DAWN. GF Fund Management CO. LTD. bought a new stake in Day One Biopharmaceuticals in the 4th quarter worth about $27,000. R Squared Ltd bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth approximately $31,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after buying an additional 1,002 shares during the last quarter. Quest Partners LLC grew its holdings in shares of Day One Biopharmaceuticals by 9,238.6% in the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after acquiring an additional 7,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Day One Biopharmaceuticals by 911.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after acquiring an additional 9,603 shares during the last quarter. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.